Testing alogliptin and Actoplus Met for diabetes and fatty liver
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests whether combining alogliptin with Actoplus Met (a type 2 diabetes medicine) can improve blood sugar, cholesterol, and pancreas health in people who have both type 2 diabetes and fatty liver disease (MAFLD). If you have not taken any diabetes medication or insulin in the past six months, this study might be a good fit for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You also have a type of fatty liver disease called MAFLD
- Your average blood sugar (HbA1c) is between 6.5% and 9.5%
- Your body mass index (BMI) is between 19 and 35
- You have not used any diabetes pills or insulin in the last 6 months
- You do not have severe heart, liver, kidney problems or an active cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding empagliflozin (a diabetes pill) to your current medicines (alogliptin and metformin) helps manage blood sugar better. It may be an option if your blood sugar is not well controlled with your current treatment.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial is testing different combinations of diabetes medicines to see which one helps keep your blood sugar more steady throughout the day. It's for people with type 2 diabetes who are already taking metformin and an SGLT-2 inhibitor but still have high blood sugar.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Hear when a new MAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.